Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: CNTA

Centessa Pharmaceuticals plc

Healthcare | Biotechnology

No licensed closing price on file for CNTA. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-1.78

Centessa Pharmaceuticals plc (NASDAQ: CNTA) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 09:05 UTC.

What Centessa Pharmaceuticals plc does

Centessa Pharmaceuticals is a clinical-stage biotechnology company developing small molecule drugs called orexin receptor 2 agonists to treat neurological and psychiatric disorders linked to problems with wakefulness, attention, cognition, and mood. The company's lead candidate, cleminorexton, is in late-stage clinical testing for disorders including narcolepsy and idiopathic hypersomnia, with two additional orexin-based candidates in earlier development stages.

Summarized from Centessa Pharmaceuticals plc’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

CNTA no longer appears among SEC's registered filers -- it may have been acquired, merged, or delisted. The figures on this page reflect the company's final filings and are no longer refreshed.
Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-1.78
Debt/equity0.23

Revenue, margins & earnings

FY2023: net loss $151M on revenue $7M$7MFY2023FY2025: net loss $198M on revenue $15M$15MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
No filings archived yet. Search EDGAR ↗
Recent Insider Activity
Source: SEC EDGAR · Filed 2026-06-24
Most recent filed transactions — June 2026:
  • 2026-06-24DirectorShare Option (right to buy)Returned to company-48,000—
  • 2026-06-24DirectorShare Option (right to buy)Returned to company-208,474—
  • 2026-06-24DirectorShare Option (right to buy)Returned to company-48,000—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Centessa Pharmaceuticals plc do?

Centessa Pharmaceuticals is a clinical-stage biotechnology company developing small molecule drugs called orexin receptor 2 agonists to treat neurological and psychiatric disorders linked to problems with wakefulness, attention, cognition, and mood.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 09:05 UTC. This page is also available as JSON at /api/data?ticker=CNTA and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for CNTA and 5,000+ tickers.

Create a free account — keep CNTA
For your agent
GET /api/data?ticker=CNTA

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt